89bio to present additional pegozafermin data at easl international liver congress™ 2022

San francisco, june 21, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (nash) will be presented at the european association for the study of the liver (easl) international liver congress™ 2022, to be held in london, uk on june 22-26, 2022.
ETNB Ratings Summary
ETNB Quant Ranking